KCT0007146尚未招募未知
A prospective, randomized, parallel design study to prove the superiority of Xalost S eye drops compared to RysmonTG eye drops 0.25% in the aspects of optic disc and macular vessel density in subjects with open-angle glaucoma and ocular hypertension
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19?(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Those who aged 19 or order and who willing to comply with all treatment and follow-up test procedures.
- •2.Those who diagnosed OAG(Primary Open Angle Glaucoma[POAG], pigmentary glaucoma, pseudoexfoliative glaucoma) or OHT
- •3.Those who with a maximum calibration vision of +0.60 logMAR or less(Snellen equivalent of 20/80 or more) in each eye
- •4.Those who with central Corneal Thickness = 480 µm and = 600 µm in each eye
- •5.Those who with 2grade or more grade(Shaffer scales) of gonioscopy
- •6.Subjest must meet the following criteria at the time of their second visit(baseline)
- •-Completed the required standby/restraint period.
- •-All IOP results are 25mmHg or less in each eyes
排除标准
- •1.A woman who is pregnant, breastfeeding, or planning to conceive.
- •2.Those who disagrees with contraception among female childbearing patients during the clinical trial period.
- •3.Subject to test for known or suspected abuse of drugs or alcohol.
- •4.Those who are currently participating or planning to participate in other clinical trials related to clinical drugs or medical devices within 4 weeks prior to the first visit (screening) or at any time during this trial period.
- •5. Those who intend to use the following prohibited drugs during the test period or are currently using them.
- •*sodium chloride/ potassium chloride eye drops, anti-cataract agent(e.g., Glutathione, pirenoxine, Vitamin B12(ex. cyanocobalamine])), all eye drops except for IPs
- •*All systemic IOP reducers (e.g., oral or intravenous CAI, oral glycerol).
- •*All eyes, around the eyes, inhalation, nasal or systemic corticosteroids.
- •6. Those who cannot safely discontinue the use of intraocular pressure reducer during the atmospheric/rest period.
- •7.Any systemic or topical drug known to affect IOP(e.g., ß-adrenaline antagonists, ß-adrenaline agents, calcium channel blockers, angiotensin-converting enzyme [ACE] inhibitors, angiotensin II receptor blockers (ARB]) to be tested or controlled.)
- •8.Patient with the past history of corneal refractive correction surgery in either way.
- •9.Patient with the history of specific ophthalmic surgery (e.g., laser fibroblast, filtration, minimally invasive glaucoma surgery (MIGS) or fibroblastotomy) to lower IOP in either eye.
- •10.Patient with past history of corneal refractive correction surgery in either eye.
- •11.Those who has allergies, hypersensitivities, or prohibition about Prostaglandin, benzalkonium chloride (BAK) or any other components in Investigational Products, or any other procedures/drugs for any tests in this Clinical trial
- •12.Any eyes that have active Glaucoma (Ex. Below -12 dB of mean deviation of visual field test
- •13.Any eyes that have cornea abnormalities or status that can interrupt or block measuring Goldman’s applanation tonometer with reliability (Ex. Fuchs Endothelial Corneal Dystrophy, FECD or any other abnormalities with clinically significant)
- •14. Any eyes that have active serious corneal and anterior segment diseases, inflammation, or eye and/or eyelid infection in either eye.
- •15. Any eyes that have Macular edema with clinically significant
- •16.Any eyes that have had medical history of serious external injuries
- •17.Any eyes that have had medical history of iritis and/or uveitis
- •18.Any eyes that have medical history of Retinal Detachment, proliferative diabetic retinopathy (PDR), or any other Retinal diseases that may have progressed over the time course of the trial.
- •19.Those who are ineligible to participate in clinical trials for the reason of any medical issues as judged by the investigators .
研究者
相似试验
已完成
Unknown
A study to compare two conjunctival approaches:forniceal versus single snip paralimbal in each pateint scheduled for bilateral symmetrical horizontal strabismus surgery, randomizing one eye to either a forniceal approach or a paralimbal approach.CTRI/2023/03/050474mme Summaiyya30
进行中（未招募）
1 期
A study to evaluate the effect of changing HIV medication (from a protease inhibitor or efavirenz to raltegravir) on liver fat, fat tissue and metabolic parameters (blood sugar and cholesterol, etc) in overweight or obese patients with metabolic problems.Study subjects are HIV infected patients with BMI>25kg/m2 and who have at least one metabolic syndrome component or a fatty liver disease.EUCTR2017-003430-85-FIHelsinki University Hospital45
进行中（未招募）
不适用
An open label, randomized, parallel design study to investigate the efficacy and safety of sevelamer hydrochloride (Renagel®) compared with calcium acetate in peritoneal dialysis patients (REN00304)EUCTR2004-002174-32-DKGenzyme Europe BV150
进行中（未招募）
1 期
An open label, randomized, parallel design study to investigate the efficacy and safety of sevelamer hydrochloride (Renagel®) compared with calcium acetate in peritoneal dialysis patients (REN00304)Estudio abierto, aleatorizado, con grupos paralelos, para investigar la eficacia y la seguridad del clorhidrato de sevelamer (Renagel) en comparación al acetato de calcio en pacientes sometidos a diálisis peritoneal.Peritoneal dialysisMedDRA version: 7.0Level: LLTClassification code 10034660EUCTR2004-002174-32-ESGenzyme Europe BV200
进行中（未招募）
1 期
An open label, randomized, parallel design study to investigate the efficacy and safety of sevelamer hydrochloride (Renagel®) compared with calcium acetate in peritoneal dialysis patients (REN00304)EUCTR2004-002174-32-GBGenzyme Europe BV250